Everything below concerns PPARδ agonist. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-05-08. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Published human data are sparse and mostly come from early-phase trials. Those studies examined short-term changes in lipids, glucose, and exercise capacity, but they were not large enough to establish efficacy or long-term safety. Some animal experiments reported increased running endurance, yet such findings do not prove a performance benefit in people. Anti-doping laboratories detect GW501516 and its metabolites in urine or blood using liquid chromatography-tandem mass spectrometry. Detection windows depend on dose, sample type, and individual metabolism. The method is sensitive enough to identify trace residues in tested samples.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ | Nuclear receptor; not androgen receptor |
| Studied indications | Dyslipidemia; obesity; diabetes | Early clinical research; development discontinued |
| Rodent toxicity | Tumor formation in multiple tissues | Dose-dependent findings in some studies |
| Human approval | None | No approved therapeutic use |
| Typical analytical method | LC-MS/MS | Used for identity and quantification |
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
N-acyl phosphatidylethanolamine phospholipase D (NAPE-PLD) is an enzyme that catalyzes the release of N-acylethanolamine (NAE) from N-acyl-phosphatidylethanolamine (NAPE). This is a major part of the process that converts ordinary lipids into chemical signals like anandamide and oleoylethanolamine. In humans, the NAPE-PLD protein is encoded by the NAPEPLD gene.
=== Frontier Capital === While Knoxville's population grew steadily in the early 1800s, most new arrivals were westward-bound migrants staying in the town for a brief period. By 1807, some 200 migrants were passing through the town every day. Cattle drovers, who specialized in driving herds of cattle across the mountains to markets in South Carolina, were also frequent visitors to the city. The city's merchants acquired goods from Baltimore and Philadelphia via wagon trains. French botanist André Michaux visited Knoxville in 1802, and reported the presence of approximately 100 houses and 10 "well-stocked" stores. While there was "brisk commerce" at the city's stores, Michaux noted, the only industries in the city were tanneries and blacksmiths. In February 1804, itinerant Methodist preacher Lorenzo Dow passed through Knoxville, and reported the widespread presence of a religious phenomenon in which worshippers would fall to the ground and go into seizure-like convulsions, or "jerks," at religious rallies. Illinois governor John Reynolds, who studied law in Knoxville, recalled a raucous, anti-British celebration held in the city on July 4, 1812, at the onset of the War of 1812. On October 27, 1815, Knoxville officially incorporated as a city. The city's new charter set up an alderman-mayor form of government, in which a Board of Aldermen was popularly elected, and in turn selected a mayor from one of their own.
== History == EFLM was created from the merger of two precursor organisations, The Federation of European Societies of Clinical Chemistry (FESCC), (a European representative of the International Federation of Clinical Chemistry and Laboratory Medicine, IFCC) and the European Community Confederation of Clinical Chemistry (EC4) at the EuroMedlab meeting in Amsterdam in 2007. Both precursor organizations arose in the 1970s. The increasing overlap between the European Union, represented by EC4 and FESCC, representing geographical Europe, meant that merger was appropriate.
Sources: en.wikipedia.org
== Main applications == DMG-PEG 2000 has similar chemical properties to the phospholipids that make up the cell membrane. This enables lipid nanoparticles composed of it to easily merge with the cell membrane, delivering its contents.
She concluded "I find it somewhat difficult to believe that, in a single raid, we find two new forms of Captagon." Videos compiled by the Israeli government of the Hamas attack—cobbled together from cell phones, GoPros, as well as car and surveillance cameras—allege that at least some of the militants were under the influence of the drug. Rose also said that "Fighters might have taken cocaine right before, or captagon, or no substances at all. Some might have taken caffeine, some may be sleep deprived...but there's no way that captagon was a factor to blame in the violence and atrocities that we witnessed on October 7".
Taylor (2015) reported that the perceived self-efficacy and perceived helplessness subscales tended to estimate scores reliably across levels of the latent variables except among respondents with exceptionally low levels of perceived helplessness and exceptionally high levels of perceived self-efficacy. Finally, much less is known about the reliability of scores from the 4-item form.
=== Combined with statins === Extended release nicotinic acid was combined with lovastatin (Advicor), and with simvastatin (Simcor), as prescription drug combinations. The combination niacin/lovastatin was approved by the US Food and Drug Administration (FDA) in 2001. The combination niacin/simvastatin was approved by the FDA in 2008. Subsequently, large outcome trials using these nicotinic acid and statin therapies were unable to demonstrate incremental benefit of nicotinic acid beyond statin therapy alone. The FDA withdrew approval of both drugs in 2016. The reason given: "Based on the collective evidence from several large cardiovascular outcome trials, the Agency has concluded that the totality of the scientific evidence no longer supports the conclusion that a drug-induced reduction in triglyceride levels and/or increase in HDL-cholesterol levels in statin-treated patients results in a reduction in the risk of cardiovascular events." The drug company discontinued the drugs.
Sources: en.wikipedia.org
== Cultivation == Some varieties and hybrids have been in Western cultivation for the last 100 to 150 years. There is now a wide array of new Chinese species being cultivated in the West, many of which have only recently been discovered, and some of which have yet to be named. There are also many older Japanese hybrids and forms, extending the boundaries of the genus in cultivation. The majority of the Chinese species have not been fully tested for hardiness nor indeed for any other aspect of their culture. The initial assumption that the plants would only thrive where their native conditions could be closely replicated have proven to be overly cautious, as most varieties are proving extraordinarily amenable to general garden and container cultivation. The cultivar 'Amber Queen' is a recipient of the Royal Horticultural Society's Award of Garden Merit.
Some unregulated transdermal progesterone products contain "wild yam extract" derived from Dioscorea villosa, but there is no evidence that the human body can convert its active ingredient (diosgenin, the plant steroid that is chemically converted to produce progesterone industrially) into progesterone.
=== 7 August === Sudanese prosecutors charged Hemedti and 16 other TASIS leaders with committing war crimes in El Fasher and South Kordofan. Three SLM officials (Legal Advisor Mahmoud Koreina, Economic Affairs Advisor Adam al-Nur, and Media Advisor Mustafa al-Jamil) announced the formation of a splinter faction in Uganda following their dismissal by Minni Minawi. Eighteen people were killed in RSF attacks on the villages of Markaz Al-Ziyadia and Lamina al-Ziyadiyah in North Kordofan.
Cheaper, faster, and smarter POCT devices have increased the use of POCT approaches by making it cost-effective for many diseases, such as diabetes, carpal tunnel syndrome (CTS) and acute coronary syndrome. Additionally, it is very desirable to measure various analytes simultaneously in the same specimen, allowing a rapid, low-cost, and reliable quantification. Therefore, multiplexed point-of-care testing (xPOCT) has become more important for medical diagnostics in the last decade. Many point-of-care test systems are realized as easy-to-use membrane-based test strips, often enclosed by a plastic test cassette. This concept often is realized in test systems for detecting pathogens, the most common being COVID-19 rapid tests. Very recently such test systems for rheumatology diagnostics have been developed, too. These tests require only a single drop of whole blood, urine or saliva, and they can be performed and interpreted by any general physician within minutes. Recently, a portable medical diagnostic device called "BioPoC" has been reported which employs free-standing enzyme-modified responsive polymer membrane-based biosensors and a newly devised low-cost transduction principle for the detection of H. pylori and urea. During the COVID-19 pandemic, rapid development of POCT occurred, aiming to improve the turnaround time and ease of use compared to the gold standard lab-based PCR test. These have included rapid antigen tests, alternate nucleic acid amplification methods, and novel sensors.
== History == Loren Pickart (1938–2023) isolated the copper peptide GHK-Cu from human plasma albumin in 1973. It was noticed that liver tissue obtained from patients aged 60 to 80 years had an increased level of fibrinogen. However, when liver cells from old patients were incubated in the blood from the younger group, the older cells started functioning in nearly the same way as the younger liver tissue. It turned out that this effect was due to a small peptide factor that behaved similarly to the synthetic peptide glycyl-L-histidyl-L-lysine (GHK). Pickart proposed that this activity in human plasma albumin was a tripeptide glycyl-L-histidyl-L-lysine and that it might function by chelating metal ions. In 1977, the growth modulating peptide was shown to be a glycyl-L-histidyl-L-lysine. It is proposed that GHK-Cu modulates copper intake into cells.
Sources: en.wikipedia.org
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.
Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.
Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.
Anti-doping and clinical laboratories commonly use liquid chromatography-tandem mass spectrometry. The method can identify GW501516 and its metabolites in urine or blood. Detection depends on sample timing and the amount present.